PRGO Stock Recent News

Perrigo Company plc provides over-the-counter health and wellness solutions after recently divesting its prescription businesses. Perrigo stock is reasonably valued at under 14 times forward earnings with a 3% dividend yield. Time to Buy, Sell, or Hold?  An analysis follows below.

DUBLIN , Aug. 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that CFO Eduardo Bezerra is scheduled to participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference in Boston, MA on Thursday, September 7 th, 2023. Separately, President and CEO, Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Piper Sandler Growth Frontiers Conference in Nashville, TN on Tuesday, September 12 th, 2023, at 11:00 AM EDT.

Perrigo Company plc (NYSE:PRGO ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Taylor - President and Chief Executive Officer Eduardo Bezerra - Executive Vice President and Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Alec Legg - Canaccord Genuity Daniel Biolsi - Hedgeye Operator Good Day and welcome to the Perrigo Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Perrigo (PRGO) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.43 per share a year ago.

DUBLIN , July 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call beginning at 8:30 A.M. (EST). Separately, President and CEO, Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference in Boston on Wednesday, August 9 th at 10:30 A.M.

Perrigo's birth control pill, Opill, can now be sold without a prescription. It'll likely start to nibble on the market shares of most other contraceptive methods.

Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.

Perrigo (NYSE: PRGO ) stock is rising on Friday as investors react to the company's over-the-counter birth control pill getting FDA approval. This is a major win for Perrigo stock as it marks the first time that the FDA has approved a daily over-the-counter birth control pill.